sweet kakoii - saved me finding it
So.... they have the IP - worth knowing because Cellspray in terms of product is the rain maker.
ReCell is limited to 2% of the patient's body surface area - so it is for just minor and usually cosmetic surgery.
Cellspray is for up to 90% of the body whilst CellsprayXP is much quicker but covers 30%
Interesting that I scoured every AVH report and never found that 2% max body area anywhere.
Referring to CCE's presentaion:http://www.asx.com.au/asx/statistics/displayAnnouncement.do?display=pdf&idsId=00448809
The applicable global market for ReCell is $1.7billion dollars whilst the Cellspray market is $5billlion
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.68 |
Change
0.045(2.76%) |
Mkt cap ! $116.4M | |||
| Open | High | Low | Value | Volume |
| $1.64 | $1.70 | $1.64 | $194.1K | 116.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 204 | $1.68 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.70 | 5000 | 1 |
View Market Depth
| Last trade - 16.10pm 02/07/2025 (20 minute delay) ? |
| AVH (ASX) Chart |